Pegram outlines exciting developments in HER2+ metastatic breast cancer
welcome to OncLive on the air®! I’m your host today, Caroline Seymour.
OncLive on the air® is a podcast by Live®, which provides oncology professionals with the resources and information they need to provide the best patient care. In digital and printed format, Live® covers all aspects of oncology practice, from new technologies to therapeutic advances to important regulatory decisions.
In today’s episode, sponsored by Seagen, we had the pleasure of speaking with Mark Pegram, MD, Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology and Associate Dean for Clinical Research Quality at the Stanford University School of Medicine and Associate Director of Clinical Research at the Stanford Comprehensive Cancer Institute (SCCI). Pegram joined us to discuss treatment sequencing in HER2-positive metastatic breast cancer.
Numerous recent trials and approvals have paved the way for exciting treatment opportunities for breast cancer. For example, in May 2022, the FDA approved fam-trastuzumab deruxtecan-nxki (Enhertu) as a second-line treatment for adult patients with unresectable or metastatic HER2-positive breast cancer, based on results from the Phase 3 DESTINY-Breast03 trial (NCT03529110). This trial showed that treatment with trastuzumab deruxtecan provided superior progression-free survival (PFS) and overall survival (OS) compared to ado-trastuzumab emtansine (T-DM1; Kadcyla).
In our exclusive interview, Pegram discussed treatment sequencing approaches, the influence of the DESTINY-Breast03 trial (NCT03529110) on the breast cancer treatment paradigm, and ongoing research in the field.
Thanks for listening to this episode of OncLive on the air®, sponsored by Seagen. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the field of oncology.
For more oncology updates, be sure to visit www.OncLive.com and sign up for our e-newsletters.
Live® is also on social media. On Twitter, follow us on @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive on the air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms*, to receive a notification whenever a new episode is released. While you’re at it, please take a moment to rate us!
Thanks again for listening OncLive on the air®.
*OncLive on the air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic and TuneIn.